Regentis Biomaterials Advances GelrinC as Off-the-Shelf Solution for Knee Cartilage Repair, Targeting a 472,500-Procedure Gap
Regentis Biomaterials is developing GelrinC, a cell-free hydrogel implant for knee cartilage repair, which could fill a market gap as no approved off-the-shelf regenerative solution exists in the U.S., with a pivotal FDA trial now over 50% enrolled and a new manufacturing process boosting yield by 400%.
Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its lead product, GelrinC, as a potential off-the-shelf solution for knee cartilage repair, addressing a significant unmet need in the U.S. market. Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved ready-to-use implant capable of regenerating hyaline-like cartilage is currently available. GelrinC, a cell-free hydrogel implant, is designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, offering a simpler alternative to existing therapies.
Articular cartilage, which lines the ends of bones in joints, has limited natural healing ability due to its lack of blood supply. Current treatments, such as microfracture, provide short-term symptom relief but often fail to produce durable cartilage long-term. More advanced cell-based therapies are complex, costly, and require lengthy manufacturing delays, limiting their widespread adoption. Regentis is positioning GelrinC as a regenerative solution that combines procedural simplicity with sustained outcomes, supported by clinical data showing durability over extended follow-up periods.
The company has achieved CE Mark approval in Europe and is now conducting a pivotal U.S. FDA trial, which is more than 50% enrolled. A newly patented solvent-free manufacturing process has increased GelrinC production yield by 400%, signaling preparation for commercial scale-up as clinical and regulatory milestones approach. This manufacturing advancement is critical for meeting potential demand if the product receives FDA approval.
Regentis Biomaterials (NYSE American: RGNT) is targeting the gap in the knee cartilage repair market with its cell-free platform, aiming to provide a truly regenerative option that avoids the drawbacks of current standards of care. The company’s progress in clinical trials and manufacturing efficiency underscores its commitment to bringing an off-the-shelf solution to patients and surgeons.
For more information on Regentis Biomaterials, visit the company’s newsroom at https://ibn.fm/RGNT.